Yinghong Wang, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, explores the impact of proton pump inhibitor (PPI) use on gastrointestinal (GI) toxicities in cancer patients treated with checkpoint inhibitors (ICIs). PPIs were associated with a higher incidence of upper GI immune-related adverse events (irAEs) and more severe lower GI irAEs, including increased hospitalization and steroid treatment. PPI use also correlated with more frequent severe diarrhea and colitis, suggesting careful consideration of PPI use during ICI therapy. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
